Unknown

Dataset Information

MTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.


ABSTRACT:

Background

Systemic therapy has proven only marginal effects in hepatocellular carcinoma (HCC) so far. The aim of this study was to evaluate the effect of targeting fibroblast growth factor receptor (FGFR) on tumour and stromal cells in HCC models.

Methods

Human and murine HCC cells, endothelial cells (ECs), vascular smooth muscle cells (VSMCs), hepatic stellate cells (HSCs), human HCC samples, FGFR inhibitor BGJ398 and mammalian target of rapamycin (mTOR) inhibitor rapamycin were used. Effects on growth, motility, signalling and angiogenic markers were determined. In vivo subcutaneous and syngeneic orthotopic tumour models were used.

Results

In tumour cells and ECs, targeting FGFR showed significant inhibitory effects on signalling and motility. Minor effects of FGFR

SUBMITTER: Scheller T 

PROVIDER: S-EPMC4453944 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature